Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up
NCT ID: NCT00795496
Last Updated: 2011-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2008-11-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesis is that when the skin condition improves in patients with AD the brochial hyperreactivity improves. The investigators also want to study whether different treatments play a role in the development or resolution of bronchial hyperreactivity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis
NCT00310492
Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels
NCT00616096
Prospective Longitudinal Observational Research in Atopic Dermatitis
NCT04240522
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359
Study to Assess the Effect of "Eucerin AtopiControl" on Dermal Symptoms in Patients With Atopic Dermatitis
NCT03315611
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The testing in the study (bronchial hyperreactivity, skin prick testing, serum IgE) is cross-sectional, but we retrospectively collect data from the last 10 years about the skin condition and medication for atopic diseases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AD patients
AD patients who fulfill the inclusion criteria for the study
Histamine provocation
A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
Skin prick tests
Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
Serum IgE blood testing
One blood test to measure total serum IgE
Mantoux-testing
Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Histamine provocation
A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
Skin prick tests
Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
Serum IgE blood testing
One blood test to measure total serum IgE
Mantoux-testing
Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient was tested for bronchial hyperreactivity in the years 1998-2000
* Patient gives signed informed consent to participate in this study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Helsinki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Helsinki University Central Hospital, Department of Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sakari Reitamo, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Skin- and Allergy Hospital, Dep. of Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skin- and Allergy Hospital, Department of Dermatology
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Virtanen H, Remitz A, Malmberg P, Rytila P, Metso T, Haahtela T, Reitamo S. Topical tacrolimus in the treatment of atopic dermatitis--does it benefit the airways? A 4-year open follow-up. J Allergy Clin Immunol. 2007 Dec;120(6):1464-6. doi: 10.1016/j.jaci.2007.08.021. Epub 2007 Oct 1. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
232685
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.